Novartis and Amgen have become embroiled in a legal row over rights to the migraine prevention drug Aimovig, as sales of a new class of injected drugs begin to mount.
A pharma company’s core mission is to improve patient outcomes. This hinges on effectively influencing HCP clinical behaviour and driving disease education.